Nabilone
As of the edition of 20 October 2026, Nabilone is a small molecule: marketed, first approved in 1982 (CA); acts on CNR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1985
- Kind
- Small molecule
- Brand name
- Cesamet
- First approved
- 31 December 1982 (CA)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Bausch Health
- Registered trials
- 24, 4 stopped early
- Disease areas
- Nervous system; Mental health; Chemically induced; Bones, joints and muscles; Cancer; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CNR1 | Cannabinoid receptor 1 | P21554 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 7 | 3 | 0 | 3 |
| Phase 3 | 7 | 4 | 1 | 0 |
| Phase 4 | 6 | 5 | 0 | 1 |
| All trials | 24 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bausch Health | Acquired holder | 1982 to now |
| Eli Lilly | Applicant | 1985 to now |